US PFAS phaseout bill proposes sweeping ban under Forever Chemical Regulation Act 2026

Dr Steven Brennan
Dr Steven Brennan
3 min readAI-drafted, expert reviewed
Industrial production equipment associated with fluorinated materials
A new US Senate bill, the Forever Chemical Regulation and Accountability Act of 2026, proposes a comprehensive phaseout of per- and polyfluoroalkyl substances (PFAS), signalling a potential paradigm shift for chemical regulation, manufacturing and product design. Introduced on 19 March 2026, the legislation targets nonessential PFAS uses, mandates reporting and sets a 10-year timeline to eliminate releases into the environment. The proposal has wide-reaching implications for industries including textiles, packaging, electronics and energy, where PFAS are valued for durability and resistance properties.

PFAS phaseout timeline and regulatory framework

The bill establishes a structured phaseout of nonessential PFAS uses within 10 years of enactment. All uses would be prohibited unless explicitly designated as “essential”, defined as critical for health, safety or societal functioning with no safer alternatives available. Manufacturers and users would be required to submit phaseout plans within three years, alongside annual reporting on volumes, uses, releases and exposure risks. The Environmental Protection Agency (EPA) would oversee compliance, data validation and public disclosure. Notably, the legislation also proposes a complete ban on PFAS releases above detectable levels within the same 10-year timeframe, backed by enforceable monitoring and inspection powers.

Accelerated bans across consumer products

The bill introduces accelerated restrictions on PFAS in consumer goods: Within 1 year: carpets, food packaging, juvenile products and fabric treatments Within 2 years: cosmetics, indoor textiles and apparel Within 4–5 years: outdoor furnishings and specialised apparel These timelines significantly compress substitution windows for consumer-facing sectors and could disrupt supply chains reliant on fluorinated chemistries.

Essential use concept and scientific oversight

A central feature is the adoption of an “essential use” framework, aligned with international regulatory trends. The National Academies would be tasked with evaluating PFAS applications and advising on prioritisation for phaseout. Essential uses must meet strict criteria, including lack of safer alternatives and necessity for societal functioning. This introduces a dynamic regulatory mechanism, allowing periodic reassessment as new data emerges.

Data, fees and enforcement measures

The bill includes robust compliance tools: Mandatory annual reporting with detailed exposure and toxicity data Fees for submissions, potentially set at $100,000 per report or petition Civil and criminal penalties for non-compliance Citizen suit provisions enabling legal action It also strengthens transparency by requiring public access to submitted data, subject to confidentiality protections.

Implications for the chemicals value chain

If enacted, the Forever Chemical Regulation Act would reshape the US chemicals landscape. Manufacturers must accelerate R&D into alternatives, while downstream users face urgent reformulation and procurement shifts. Financial exposure may increase due to liability provisions, including expanded rights for damages linked to hazardous substance exposure. Investors and insurers are likely to reassess PFAS-related risks.

Outlook for PFAS regulation

The bill reflects growing political momentum to address PFAS contamination, often termed “forever chemicals” due to their persistence and bioaccumulation. While still subject to legislative debate, the proposal signals a tightening regulatory trajectory that aligns with global efforts to restrict PFAS use and emissions.
Get weekly regulatory updates:

Related Articles

Join 3,500+ professionals staying ahead

Subscribe to Foresight Weekly for expert-picked regulatory developments across chemicals, sustainability, product safety, ESG, and HSE.

Free forever. Unsubscribe anytime.

Read by professionals at

Boeing
AstraZeneca
Siemens
PepsiCo
SpaceX